SEC Comment Letter 0000000000-24-004983 to Xilio Therapeutics, Inc. (XLO)
Xilio Therapeutics, Inc.
Date: May 2, 2024 · CIK: 0001840233 · Accession: 0000000000-24-004983
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-279015
Letter
United States securities and exchange commission logo May 2, 2024 René Russo, Pharm.D. President and Chief Executive Officer Xilio Therapeutics, Inc. 828 Winter Street, Suite 300 Waltham, Massachusetts 02451 Re:Xilio Therapeutics, Inc. Registration Statement on Form S-3 Filed April 30, 2024 File No. 333-279015 Dear René Russo: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Molly W. Fox, Esq.
Show Raw Text
United States securities and exchange commission logo
May 2, 2024
René Russo, Pharm.D.
President and Chief Executive Officer
Xilio Therapeutics, Inc.
828 Winter Street, Suite 300
Waltham, Massachusetts 02451
Re:Xilio Therapeutics, Inc.
Registration Statement on Form S-3
Filed April 30, 2024
File No. 333-279015
Dear René Russo:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at 202-551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Molly W. Fox, Esq.